…coronary syndrome. The available evidence supports consideration of low dose colchicine as an adjunct to, rather than a replacement for, established secondary prevention treatment. Its…

…or severity; angina that awakens the patient from sleep. Patients receiving modified antiplatelet therapy require clinical surveillance for both recurrent ischemia and bleeding. The source…

…statin therapy remains the foundation of lipid lowering treatment for patients with chronic coronary syndrome, acute coronary syndrome (ACS), atherosclerotic peripheral arterial disease, and other…

…more common in women than in men and can last for years. ACE Inhibitor Induced Angioedema Angioedema secondary to ACE inhibitor therapy occurs in approximately…

…skeletal muscle, a pharmacological feature that may limit muscle related toxicity despite bempedoic acid acting within the same broad cholesterol synthesis pathway as statins. The…

…should not be used. Specific dosing adjustments are required in certain patient populations: Pediatric patients: For patients weighing less than 50 kg, the dosing should…

…persistence with prescribed therapy; Inadequate dosing; An inappropriate diuretic for kidney function; Excess dietary sodium and volume overload; Concomitant drugs or conditions that increase blood…

…or atheroembolic material, but pharmacological and mechanical strategies directed specifically at reperfusion injury have not generally demonstrated sufficient clinical benefit for routine use. No reflow…

…triglyceride rich lipoproteins in addition to LDL and other apoB containing particles. Cardiovascular risk categories Primary prevention For adults aged 40–75 years without diabetes…

…and thus the selection between them may be guided by individual patient needs rather than by a distinct advantage of one drug over the other…